NEW YORK, NY — (Marketwire) — 11/18/09 — Vivakor, Inc. (OTCBB: VIVK) announced yesterday that its Board of Directors approved a dividend to share holders of record for December 1, 2009. Each shareholder will receive one (1) share of HealthAmerica, Inc. for every one (1) share of Vivakor, Inc. pending FINRA approval.

HealthAmerica, Inc. is in the process of developing a patented magnetic resonance imaging (MRI) image resolution enhancing technology called VIVASlices. With the sales of all medical devices slowing, a need for clearer more efficient machines is arising. With the decrease in sales of medical devices like MRIs, facilities are demanding more out of their machines and require them to produce better results.

It is estimated there are between 7,000 and 10,000 MRI machines in use in the United States alone. VIVASlices with its easy to use user interface will work on low, mid and high field magnets, opening

...

Nov. 17, 2009 (PR Newswire) — CORALVILLE, Iowa, Nov. 17 /PRNewswire-FirstCall/ — Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced that its Board of Directors approved a dividend of shares of common stock of HealthAmerica, Inc., a Nevada corporation of which Vivakor owns approximately 84% of the outstanding common stock. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on the record date. The record date for the distribution is expected to be December 1, 2009, subject to review and approval of FINRA, and the distribution date is expected to be December 9, 2009. After the dividend distribution, Vivakor will continue to own approximately 62% of the outstanding common stock of HealthAmerica.

Vivakor shareholders will not be required to take any action to receive the HealthAmerica common shares on the distribution date.

Vivakor Chairman Matt Nicosia

...

Lifeline Biotechnologies Inc.

(Public, PINK:LLBO)

With the recent gains in Hard to Treat Diseases Inc. (PINK:HTDS) and BioElectronics Corp. (OTC:BIEL), investors were left hungry for more undervalued, high potential biotech companies — Then came LifeLine Biotechnologies Inc (OTC:LLBO). As technology continues to redefine the modern era of medical advancements, certain companies will stand apart from the rest, as is the case with Lifeline Biotechnologies Inc. This company is an innovative medical technology company committed to the improvement of the quality of life through exceptional health care systems, focusing on prevention, early diagnosis, and quick recovery. Recently, the company has made headlines with their innovative Breast Cancer detection system, the First Warning System ™, a dynamic test which collects information over time with an uncanny efficacy. The next several months will prove to be critical for LifeLine Biotechnologies, as they await the FDA’s decision

...

Imaging3, Inc.

(Public, OTC:IMGG)

A new and radical medical device from Imaging3 Inc. (OTC:IMGG) is ready to set the standard, and revolutionize the way we look at X-ray, MRI and CT scans. Imaging 3 is currently awaiting FDA approval on their DViS (Dominion Volumetric Imaging Scanner). Currently, medical imaging is met with challenges of long waits, lack of space, lack of mobility, and limited uses. However, for the first time ever, health-care workers will be able to instantly view 3D, high-resolution images of virtually any part of the human body. Thus, Imaging 3 looks to change all that. Saving time, saving lives and reducing costs. This technology will “set the standard for the next 10 years.” The following article was composed by StocksHaven Investments alongside Professor Philip Runfeldt, a Behavioral Analyst who has worked with Fortune 500 companies and major Universities throughout

...

Earlier this week, the US Food and Drug Administration (FDA) approved Novartis Pharma’s (NVS) Extavia, a branded version of interferon beta-1b, which is used for the treatment of multiple sclerosis (MS). Novartis obtained the rights to seek approval for its own branded version of interferon beta-1b through agreements signed with Bayer Schering, which markets Betaseron. MS is a chronic autoimmune disease in which the body's immune system attacks the myelin sheath, or protective tissue surrounding the nerve fibers that carry electrical signals in the brain. As a result, persons afflicted with the disease experience problems with muscle control and strength, vision, balance, sensation and mental function. Extavia has been approved for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. It is also indicated for patients who have experienced a first clinical episode of MS and have features consistent with ...

Trading on the NASDAQ Capital Market, iCAD, Inc. is an industry-leading provider of Computer-Aided Detection (CAD) solutions. Headquartered in Nashua, New Hampshire, with additional offices in Beavercreek, Ohio, their solutions enable healthcare professionals to serve patients better by identifying pathologies and pinpointing cancer earlier. The Company’s solutions aid in the early detection of the most prevalent cancers.

The Company received Food and Drug Administration (FDA) approval of their first breast-cancer detection product in 2002. Since then they placed more than 2,700 iCAD systems in healthcare practices around the globe. iCAD offers a comprehensive range of high-performance, upgradeable CAD systems, and workflow solutions for mammography (film-based, digital radiography and computed radiography), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Their systems are for the high, mid, and low volume mammography markets.

iCAD’s mammography CAD innovations include being the first system to offer a clear film-to-digital upgrade path, as well as the

...

Imaging3, Inc. (IMGG.OB), a medical device manufacturer and distributor, has developed a breakthrough technology that utilizes high-resolution photo-flouroscopy to produce three-dimensional medical diagnostic images. With its ability to produce real-time 3D images, Dominion™ can be used to improve any medical procedure where multiple frame references are required to perform surgery on or in the human body.

The Dominion’s patented technology can be applied to a multitude of medical areas including trauma, cardiology, pediatrics, orthopedics, vascular, neuro-vascular, and sports medicine. The real-time 3D images will allow surgeons to plan for less invasive and more precise procedures, which will reduce a patient’s risk and recovery time. In addition to 3D real-time flouroscopic imaging, the Dominion can also emulate other imaging technology, like a CT scan. Along with its high-resolution imaging capabilities, the Dominion is a mobile unit that can fit that is powered by a standard wall outlet and will fit through

...

QPC Lasers, Inc. (OTCBB: QPCI) has established themselves as a worldwide leader in the design and manufacture of high power semiconductor lasers serving the consumer, industrial, defense, and medical fields. The company is responsible for the development of a patented high brightness chip-based laser technology, possessing the potential to reduce the size, cost, and weight of lasers by as much as 10X, while at the same time dramatically improving their energy efficiency and portability. As of today, the company’s lasers are being utilized around the world in the development of next generation laser based HD-TV, cancer treatment, and laser weapons. QPC has a strong belief that their technology will enable them to capture significant market share in the markets they are targeting within the coming years.

The company’s high brightness semiconductor laser technology is enabling diode lasers to be used directly in a new range of medical and biomedical applications

...